KPTI•benzinga•
Karyopharm Therapeutics Announces Phase 3 SENTRY Trial Data For Selinexor In JAKi-Naïve Myelofibrosis Expected In H2 2025; Enrollment By H1 2025; Lori Macomber Appointed Chief Financial Officer; Preliminary 2024 Revenue At $145M And XPOVIO Sales Reached $
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga